However, PD-1 mAb treatment in the PDO model significantly upregulated TRAIL expression on infiltrated T cells (Fig. 6g, h and Supplementary Fig. S5d) and Annexin V+ MDSCs expressed higher DR5 levels (Fig. 6i and Supplementary Fig. S5e) in CRC patients, in response to PD-1 blockade therapy. The gene discussed is TNFSF10; the disease is colorectal carcinoma.